GENO.ST Stock: Genovis AB (publ.) Stock Price, Analysis & Insights
Get live GENO.ST stock price $19.58, comprehensive Genovis AB (publ.) stock analysis, charts, news, and expert forecast. Real-time GENO.ST stock data and investment insights.
Loading chart data...
Genovis AB (publ.) (GENO.ST) Overview
Genovis AB (publ.) (GENO.ST) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, GENO.ST trades at $19.58 with a market capitalization of 1.29B . Over the past 52 weeks, GENO.ST has traded between $15.64 and $29.80 , with the current price positioned at approximately 28% of this range . The stock currently tr...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 1.29B
- Current price: $19.58
- 52-week range: $15.64 - $29.80
- P/E ratio: 52.92
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Genovis AB (publ.) is a Swedish biotechnology firm that invents, develops, and commercializes advanced enzymatic tools crucial for drug discovery and development. These innovative solutions primarily cater to the pharmaceutical and medical device ind...
Company Information
- CEO
- Fredrik Olsson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
Contact Information
- Website
- https://www.genovis.com
- Address
- ScheelevAegen 2
- Country
- SE
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 52.9)
✓ Higher growth potential with elevated volatility (Beta: 1.73)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Genovis AB (publ.) shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Genovis AB (publ.)
- ⚠Investors should consider how Genovis AB (publ.) fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 52.9) requires strong growth to justify
Market Cap
1.29B
P/E Ratio (TTM)
52.92
Beta
1.73
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare GENO.ST with peer companies:
- Price
- $16.34-2.16% (1D)
- Market cap
- 1.13B
- Price
- $2.16+2.56% (1D)
- Market cap
- 537.00M
- Price
- $1.15+0.17% (1D)
- Market cap
- 154.10M
- Price
- $69.00+4.07% (1D)
- Market cap
- 827.85M
- Price
- $1.77+2.37% (1D)
- Market cap
- 402.17M
- Price
- $4.14+0.61% (1D)
- Market cap
- 457.99M
- Price
- $51.00-1.16% (1D)
- Market cap
- 1.19B
- Price
- $262.00-0.76% (1D)
- Market cap
- 2.35B
- Price
- $14.50-0.28% (1D)
- Market cap
- 770.16M
- Price
- $15.14+4.41% (1D)
- Market cap
- 717.89M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
43/100 ⭐⭐⭐
- Overall
- -1.0%
- NYSE
- -1.6%
- NASDAQ
- -0.4%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.3% | +1.3% | +1.9% | 19.8 | 83/100⭐⭐⭐⭐⭐ |
| Technology | +0.8% | +1.1% | +3.0% | 52.0 | 76/100⭐⭐⭐⭐⭐ |
| Basic Materials | +0.8% | +0.3% | +1.9% | 27.9 | 69/100⭐⭐⭐⭐ |
| Industrials | -0.3% | -0.9% | +2.7% | 43.0 | 64/100⭐⭐⭐⭐ |
| Communication Services | -0.8% | -1.3% | +0.4% | 21.9 | 48/100⭐⭐⭐ |
| Consumer Defensive | +0.6% | +1.6% | -2.5% | 31.2 | 44/100⭐⭐⭐ |
| Healthcare | -1.0% | -2.0% | +1.5% | 30.5 | 43/100⭐⭐⭐ |
| Real Estate | +0.5% | -1.1% | -0.0% | 50.0 | 33/100⭐⭐ |
| Energy | +0.5% | -3.6% | -0.0% | 35.9 | 31/100⭐⭐ |
| Utilities | +2.0% | -1.3% | -5.1% | 26.1 | 31/100⭐⭐ |
| Consumer Cyclical | -0.3% | +0.3% | -0.2% | 55.8 | 28/100⭐⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.